Sionna Therapeutics (NASDAQ:SION) CEO Michael Cloonan Sells 14,775 Shares of Stock

by · The Cerbat Gem

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) CEO Michael Cloonan sold 14,775 shares of Sionna Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $31.11, for a total value of $459,650.25. Following the transaction, the chief executive officer owned 547,343 shares in the company, valued at $17,027,840.73. This trade represents a 2.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Michael Cloonan also recently made the following trade(s):

  • On Thursday, October 16th, Michael Cloonan sold 10,425 shares of Sionna Therapeutics stock. The stock was sold at an average price of $31.51, for a total value of $328,491.75.
  • On Monday, September 29th, Michael Cloonan sold 7,793 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.70, for a total transaction of $231,452.10.
  • On Friday, September 26th, Michael Cloonan sold 17,207 shares of Sionna Therapeutics stock. The shares were sold at an average price of $28.85, for a total transaction of $496,421.95.
  • On Tuesday, August 26th, Michael Cloonan sold 17,574 shares of Sionna Therapeutics stock. The shares were sold at an average price of $24.96, for a total transaction of $438,647.04.
  • On Wednesday, August 27th, Michael Cloonan sold 7,426 shares of Sionna Therapeutics stock. The stock was sold at an average price of $25.01, for a total transaction of $185,724.26.

Sionna Therapeutics Stock Down 2.4%

SION opened at $31.93 on Friday. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $34.00. The firm’s fifty day simple moving average is $25.52 and its 200 day simple moving average is $18.51.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SION shares. Jones Trading began coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 target price on the stock. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Weiss Ratings restated a “sell (d)” rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. Royal Bank Of Canada assumed coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 target price for the company. Finally, Raymond James Financial assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $45.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

View Our Latest Report on SION

Institutional Investors Weigh In On Sionna Therapeutics

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics during the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Sionna Therapeutics in the second quarter valued at $45,000. Virtus Investment Advisers LLC bought a new position in shares of Sionna Therapeutics in the 2nd quarter valued at about $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth about $117,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at about $118,000.

Sionna Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Featured Stories